Over the last 7 days, the United States market has dropped 1.1%, but it is up 9.1% over the past year, with earnings forecast to grow by 14% annually. For those looking to invest in smaller or newer companies, penny stocks — despite their somewhat outdated name — can still offer surprising value when paired with solid financial foundations. This article highlights three such penny stocks that present compelling opportunities due to their financial strength and potential for growth.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| SideChannel (OTCPK:SDCH) | $0.052 | $11.47M | ✅ 4 ⚠️ 2 View Analysis > |
| Perfect (NYSE:PERF) | $1.79 | $184.35M | ✅ 3 ⚠️ 0 View Analysis > |
| WM Technology (NasdaqGS:MAPS) | $1.05 | $188.36M | ✅ 4 ⚠️ 1 View Analysis > |
| CureVac (NasdaqGM:CVAC) | $3.19 | $963.67M | ✅ 4 ⚠️ 0 View Analysis > |
| Flexible Solutions International (NYSEAM:FSI) | $4.35 | $56.66M | ✅ 1 ⚠️ 2 View Analysis > |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.54 | $87.41M | ✅ 3 ⚠️ 2 View Analysis > |
| Table Trac (OTCPK:TBTC) | $4.70 | $22.12M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (OTCPK:BABB) | $0.812625 | $5.88M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (NasdaqGS:LCUT) | $3.16 | $72.4M | ✅ 3 ⚠️ 2 View Analysis > |
| New Horizon Aircraft (NasdaqCM:HOVR) | $0.9001 | $28.87M | ✅ 3 ⚠️ 6 View Analysis > |
Click here to see the full list of 735 stocks from our US Penny Stocks screener.
Here's a peek at a few of the choices from the screener.
Allogene Therapeutics (NasdaqGS:ALLO)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases, with a market cap of approximately $253.73 million.
Operations: Allogene Therapeutics, Inc. has not reported any revenue segments.
Market Cap: $253.73M
Allogene Therapeutics, Inc., a pre-revenue clinical-stage company with a market cap of approximately US$253.73 million, is focused on developing allogeneic T cell therapies for cancer and autoimmune diseases. Despite being unprofitable and experiencing significant insider selling recently, the company's short-term assets exceed both its short- and long-term liabilities, providing some financial stability. Recent developments include FDA Fast Track Designations for ALLO-329 in treating autoimmune diseases and promising data from trials like TRAVERSE for ALLO-316 in renal cell carcinoma. However, the stock remains highly volatile with no profitability forecasted in the near term.
- Take a closer look at Allogene Therapeutics' potential here in our financial health report.
- Understand Allogene Therapeutics' earnings outlook by examining our growth report.
Neumora Therapeutics (NasdaqGS:NMRA)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States, with a market cap of approximately $118.03 million.
Operations: Neumora Therapeutics, Inc. currently does not report any revenue segments.
Market Cap: $118.03M
Neumora Therapeutics, Inc., with a market cap of US$118.03 million, is a pre-revenue clinical-stage biopharmaceutical company. The firm is currently facing challenges as it received a notice from Nasdaq for non-compliance with the US$1 minimum bid price requirement, risking potential delisting unless resolved by November 2025. Despite being debt-free and having short-term assets of US$254.9 million exceeding liabilities, Neumora remains unprofitable with increasing losses reported at US$67.99 million for Q1 2025. The board has proposed a reverse stock split to maintain its Nasdaq listing status, pending shareholder approval later this month.
- Get an in-depth perspective on Neumora Therapeutics' performance by reading our balance sheet health report here.
- Gain insights into Neumora Therapeutics' future direction by reviewing our growth report.
Kidoz (OTCPK:KDOZ.F)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Kidoz Inc. operates a mobile advertising platform targeting children, teens, and families across various regions including Europe and North America, with a market cap of $32.83 million.
Operations: The company generates revenue primarily through its Ad Tech Advertising sales, totaling $14 million.
Market Cap: $32.83M
Kidoz Inc., with a market cap of US$32.83 million, operates a mobile advertising platform and has recently transitioned to profitability, reporting net income of US$0.35 million for 2024 compared to a loss the previous year. The company generated US$14 million in revenue primarily from its Ad Tech Advertising sales, marking steady growth from the prior year. Kidoz is debt-free, with short-term assets of US$8 million comfortably covering liabilities of US$3.8 million, and it trades significantly below estimated fair value. While management is relatively new with an average tenure of three years, they are considered experienced in guiding the company's financial health forward.
- Click here and access our complete financial health analysis report to understand the dynamics of Kidoz.
- Learn about Kidoz's future growth trajectory here.
Make It Happen
- Get an in-depth perspective on all 735 US Penny Stocks by using our screener here.
- Curious About Other Options? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Allogene Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com